biostudies-literatureKang EYAlberta Precision LaboratoriesWestmead Hospital Department of Gynaecological OncologyCancer Research UKUniversity of New South WalesHeuer Stiftung für medizinische ForschungInstitute of Cancer ResearchNSW Ministry of HealthAmerican Cancer SocietyVGH and UBC Hospital FoundationAssar Gabrielsson FoundationNational Cancer InstituteCancer Institute NSWUniversity of Pittsburgh Dean's Faculty Advancement FundNational Center for Research ResourcesMedical Research and Materiel CommandALF-agreementNCRR NIH HHSBreast Cancer NowSwedish Cancer FoundationU.S. Defense Health ProgramTranslational Cancer Research NetworkSydney West Translational Cancer Research CentreBC Cancer FoundationMichael Smith Foundation for Health ResearchDutch Cancer SocietyNCI NIH HHSNational Health and Medical Research Council855-871https://www.ebi.ac.uk/biostudies/studies/S-EPMC9035053biostudies-literatureUnknown480(4)Tubo-ovarian high-grade serous carcinomas (HGSC) are highly proliferative neoplasms that generally respond well to platinum/taxane chemotherapy. We recently identified minichromosome maintenance complex component 3 (MCM3), which is involved in the initiation of DNA replication and proliferation, as a favorable prognostic marker in HGSC. Our objective was to further validate whether MCM3 mRNA expression and possibly MCM3 protein levels are associated with survival in patients with HGSC. MCM3 mRNA expression was measured using NanoString expression profiling on formalin-fixed and paraffin-embedded tissue (N = 2355 HGSC) and MCM3 protein expression was assessed by immunohistochemistry (N = 522 HGSC) and compared with Ki-67. Kaplan-Meier curves and the Cox proportional hazards model were used Virchows Archiv : an international journal of pathologyMCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.PMC9035053628903K07-CA80668HU0001-19-2-0031SIOP-06-258-01-COUNP30 CA008748K07 CA080668DAMD17-02-1-0669P50-CA135393P30CA014089RS10-526P30 CA014089HU0001-16-2-0006R01 CA248288M01 RR000056R01 CA095023R01-CA24828816561R01CA17240412/RIG/1-17RS19-612IKNL2014-6838R01 CA12684115/RIG/1-16310670R01 CA172404P50 CA136393P30 CA015083MO1- RR000056NSW Health PhD Scholarship ProgramR01CA095023Heitz FKobel MHarnett PRTaylor SBoros JHogdall CKCohen PAOlbrecht Svan-Wagensveld LOdunsi KEl-Bahrawy MAJones MELycke MKonecny GChiu DSStaebler AKelemen LELester JFischer ABolithon AModugno FNeuhausen SLPearce CLHein APopovic GKarlan BYHeublein SGayther SAMeagher NSVierkant RATalhouk ATang KConrads TPHorlings HMCrowe PJSundfeldt KSteed HLoverix LYu YLaVigne-Mager KCandido Dos Reis FJCoulson POlawaiye ALambrechts DQuinn CHogdall EHuang YStewart CJRLee CHWu AHGrube Mdu Bois AErber RKennedy CJWang CEtter JLBisinotto CPharoah PDPGarcia-Donas JMillstein JPike MCHarter PWinham SJSwerdlow AJLambie NBilic SPavanello MBarquin-Garcia ABarlow ESchoemaker MJTseng CCMaxwell GLDa-Anoy AHettiaratchi AFasching PAAtaseven BTan ASasamoto NNevins NKommoss FKFLeung BLe NDYague-Fernandez MFarrell RTerry KLCook LSHirasawa ABrand AHKommoss SMateoiu CBeckmann MWNeudeck NRamus SJRuiz-Llorente SDeFazio ACramer DWLawrenson KMoysich KBHartmann AAndress JVergote IEdwards RPRuebner MArmasu SMElishaev EJoseph JCasablanca YKang EYAnglesio MSRobertson GMorgan TLeung YSinn PGoode ELfalseMCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.Tubo-ovarian high-grade serous carcinomas (HGSC) are highly proliferative neoplasms that generally respond well to platinum/taxane chemotherapy. We recently identified minichromosome maintenance complex component 3 (MCM3), which is involved in the initiation of DNA replication and proliferation, as a favorable prognostic marker in HGSC. Our objective was to further validate whether MCM3 mRNA expression and possibly MCM3 protein levels are associated with survival in patients with HGSC. MCM3 mRNA expression was measured using NanoString expression profiling on formalin-fixed and paraffin-embedded tissue (N = 2355 HGSC) and MCM3 protein expression was assessed by immunohistochemistry (N = 522 HGSC) and compared with Ki-67. Kaplan-Meier curves and the Cox proportional hazards model were used 2022-01-01T00:00:00Z2022 Apr2025-04-19T23:46:36.552Z2025-04-19T23:46:36.552ZS-EPMC90350533478293610.1007/s00428-021-03232-0